Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.39 |
| ▸ | CHKA | P35790 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 3/20 | 0.39 |
| ▸ | BCHE | P06276 | 12/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11209572 | 0.83 | BCHE (0.46) | SIGMAR1ACHEBCHE | |
| Hydrochloric Acid SCHEMBL6582411 | 0.83 | BRD4 (0.47) | CHRM5CHKAACHE | |
| SCHEMBL12420733 | 0.75 | PTGES (0.45) | KMT2A | |
| SCHEMBL27551911 | 0.74 | ALDH1A1 (0.41) | SIGMAR1ACHEALDH1A1MAPK1KMT2A | |
| SCHEMBL27528019 | 0.72 | BCHE (0.44) | ACHEBCHEALDH1A1 | |
| SCHEMBL22337207 | 0.71 | SIGMAR1 (0.45) | SIGMAR1ACHEBCHEKMT2A | |
| SCHEMBL21609721 | 0.71 | SIGMAR1 (0.45) | SIGMAR1ACHEBCHEKMT2A | |
| SCHEMBL27599165 | 0.71 | NPC1 (0.43) | SIGMAR1ACHEBCHEALDH1A1KMT2A | |
| SCHEMBL8281666 | 0.70 | CHRM5 (0.52) | CHRM5CHKA | |
| SCHEMBL14409566 | 0.70 | CHRM5 (0.52) | CHRM5CHKABCHESMN1; SMN2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1147469-C | Novel urea derivatives bearing nitrogenous aromatic heterocycles | ������ҩ��ʽ���� | 2004-04-28 | — | — | CN | disclosed |
| US-6420398-B2 | FOR TREATING AUTOIMMUNE DISEASES SUCH AS RHEUMATOID ARTHRITIS; 4-(3-(2-(ACETYLTHIO)ETHYL)-3-(2-CYCLOHEXYLETHYL)-UREIDOMETHYL)-1 -METHYLPYRIDINIUM IODIDE, FOR EXAMPLE; INHIBIT PRODUCTION OF TUMOR NECROSIS FACTOR ALPHA (TNF-A) | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2002-07-16 | — | — | US | disclosed |
| US-20010041725-A1 | Novel urea derivatives having nitrogen aromatic heterocycle | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2001-11-15 | — | — | US | disclosed |
| CN-1318051-A | Novel urea derivative having aromatic nitrogen-containing heterocycle | SANTEN PHARMACEUTICAL CO LTD (JP) | 2001-10-17 | — | — | CN | disclosed |
| EP-1103543-A1 | NOVEL UREA DERIVATIVES BEARING NITROGENOUS AROMATIC HETEROCYCLES | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2001-05-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010041725-A1 | Novel urea derivatives having nitrogen aromatic heterocycle | TNF, UACA, HRH4 | SIGMAR1 339/4885CHRM5 1244/4885CHKA 906/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.